Research

The PrEP at home study evaluates the feasibility and acceptability of remote follow-up visits, including laboratory testing, for people taking pre-exposure prophylaxis (PrEP). The study aims to determine whether participants are interested in and prepared for remote PrEP follow-up, assess their persistence in remote PrEP care at 3, 6, and 12 months, and evaluate their satisfaction with this method of care delivery. It also aims to identify any implementation needs for wider deployment of remote PrEP follow-up.

The PCORI study is comparing two mobile health technologies (a mobile app and text messaging technology) to improve adherence to HIV pre-exposure prophylaxis (PrEP) medication. The study aims to determine the effectiveness of the two technologies in increasing PrEP adherence and continuation, as measured by PrEP concentrations in dried blood spots and participant satisfaction and engagement. It also aims to assess the impact of the technologies on adherence self-efficacy and to evaluate the contextual and implementation factors that influence the uptake of each technology. Participants are followed for a year and complete surveys at 6 and 12 months.

The Purpose 2 (Gilead) trial is a Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir (LEN) for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection.

The purpose of this study is to see if LEN is safe and effective to use as PrEP and assess how effective LEN is compared to F/TDF for PrEP.

Click here to see if you qualify!

For more detailed information please contact our Infectious Disease Prevention Research Unit at the number below or visit the clinical trials website link

The Study of Tecovirimat for Human Monkeypox Virus (STOMP) trial is a Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease.

The purpose of this study is to evaluate how well tecovirimat works for the treatment of human monkeypox virus infection and if the study drug is safe in people. The study will also help us understand more about how human monkeypox causes disease and how the body fights off infection.

For more detailed information please contact our Infectious Disease Prevention Research Unit at the number below or visit the clinical trials website link